PL2134746T3 - Ludzkie, monoklonalne przeciwciało swoiste wobec nowotworu - Google Patents

Ludzkie, monoklonalne przeciwciało swoiste wobec nowotworu

Info

Publication number
PL2134746T3
PL2134746T3 PL08716518T PL08716518T PL2134746T3 PL 2134746 T3 PL2134746 T3 PL 2134746T3 PL 08716518 T PL08716518 T PL 08716518T PL 08716518 T PL08716518 T PL 08716518T PL 2134746 T3 PL2134746 T3 PL 2134746T3
Authority
PL
Poland
Prior art keywords
specific antibody
human tumor
monoclonal human
monoclonal
tumor
Prior art date
Application number
PL08716518T
Other languages
English (en)
Inventor
Christoph Esslinger
Sandra Dietschy-Kuenzle
Irene Abela
Alfred Zippelius
Dirk Jaeger
Alexander Knuth
Roger M D Nitsch
Holger Moch
Norbert Goebels
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Publication of PL2134746T3 publication Critical patent/PL2134746T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Reproductive Health (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
PL08716518T 2007-03-13 2008-03-13 Ludzkie, monoklonalne przeciwciało swoiste wobec nowotworu PL2134746T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07005180 2007-03-13
PCT/EP2008/002021 WO2008110372A1 (en) 2007-03-13 2008-03-13 Monoclonal human tumor-specific antibody
EP08716518.9A EP2134746B1 (en) 2007-03-13 2008-03-13 Monoclonal human tumor-specific antibody

Publications (1)

Publication Number Publication Date
PL2134746T3 true PL2134746T3 (pl) 2015-01-30

Family

ID=39627674

Family Applications (2)

Application Number Title Priority Date Filing Date
PL08716518T PL2134746T3 (pl) 2007-03-13 2008-03-13 Ludzkie, monoklonalne przeciwciało swoiste wobec nowotworu
PL12151047T PL2457928T3 (pl) 2007-03-13 2008-03-13 Monoklonalne ludzkie przeciwciało swoiste względem nowotworu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL12151047T PL2457928T3 (pl) 2007-03-13 2008-03-13 Monoklonalne ludzkie przeciwciało swoiste względem nowotworu

Country Status (19)

Country Link
US (2) US20110123447A1 (pl)
EP (4) EP2134746B1 (pl)
JP (2) JP2010520760A (pl)
KR (1) KR101570702B1 (pl)
CN (1) CN101652388B (pl)
AU (1) AU2008225994B9 (pl)
BR (1) BRPI0808940B8 (pl)
CA (1) CA2680914C (pl)
DK (1) DK2457928T3 (pl)
ES (2) ES2523194T3 (pl)
HU (1) HUE035762T2 (pl)
IL (1) IL200615A (pl)
MX (1) MX2009009926A (pl)
NZ (1) NZ579520A (pl)
PL (2) PL2134746T3 (pl)
PT (1) PT2457928T (pl)
RU (1) RU2488593C2 (pl)
WO (2) WO2008110373A1 (pl)
ZA (1) ZA200905874B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
EP2186827A1 (en) 2008-11-14 2010-05-19 HS LifeSciences Ltd. Surrogate marker directed cDNA cloning of selectively induced mRNAs
WO2010069603A1 (en) 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies
CN102869682B (zh) * 2009-11-18 2016-10-19 曼康公司 单克隆抗体及其诊断用途
WO2011110642A2 (en) * 2010-03-10 2011-09-15 Genmab A/S Monoclonal antibodies against c-met
DK2663580T3 (en) 2011-01-10 2017-03-13 Ct Atlantic Ltd COMBINATION THERAPY INCLUDING TUMOR ASSOCIATED ANTI-BINDING ANTIBODIES
CN103796679B (zh) 2011-06-23 2016-10-19 比奥根国际神经科学公司 抗-α突触核蛋白结合分子
EP2797952B1 (en) 2011-12-28 2019-02-27 ImmunoQure AG Method of providing monoclonal auto-antibodies with desired specificity
US10131709B2 (en) 2011-12-28 2018-11-20 Immunoqure Ag Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
CN103382223B (zh) * 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
CN104507963B (zh) * 2012-05-22 2017-12-15 美国卫生和人力服务部 鼠抗‑ny‑eso‑1 t细胞受体
WO2015001047A1 (en) 2013-07-03 2015-01-08 Immunoqure Ag Method of providing anti-human cytokine antibodies for pharmaceutical use
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
AU2018321335B2 (en) 2017-08-22 2025-08-14 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
WO2019084538A1 (en) 2017-10-27 2019-05-02 Board Of Regents, The University Of Texas System TUMOR SPECIFIC ANTIBODIES, T CELL RECEPTORS AND METHODS OF IDENTIFICATION THEREOF
BR112021026831A2 (pt) 2019-07-03 2022-02-22 Regeneron Pharma Proteínas de ligação ao antígeno anti-carcinoma de células escamosas esofágicas new york 1 (ny-eso-1) e métodos de uso das mesmas

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US6723832B1 (en) * 1996-10-03 2004-04-20 Ludwig Institute For Cancer Research Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof
US6252052B1 (en) * 1996-10-03 2001-06-26 Cornell Research Foundation, Inc Antibodies which bind to NY-ESO-1 cancer associated proteins, and hybridomas which produce these antibodies
AU631545B2 (en) 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
EP0903408A3 (en) 1992-08-21 2005-11-02 Biogen, Inc. Tat-derived transport polypeptide
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6251603B1 (en) 1996-10-03 2001-06-26 Ludwig Institute For Cancer Research Method for determining status of a cancerous condition by determining antibodies to NY-ESO-1 in a patient sample
US7579160B2 (en) * 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US20030236209A1 (en) * 1998-03-18 2003-12-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6140050A (en) 1998-06-26 2000-10-31 Ludwig Institute For Cancer Research Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
EP1117691A1 (en) * 1998-10-05 2001-07-25 Ludwig Institute For Cancer Research Methods for producing human tumor antigen specific antibodies
AU1631700A (en) 1998-11-23 2000-06-13 Idec Pharmaceuticals Corporation Tumor antigen-specific antibody-gp39 chimeric protein constructs
DE19903525A1 (de) 1999-01-29 2000-08-03 Mewa Recycling Maschinen Und A Zerlegungseinrichtung für Altgeräte
AU2003284427A1 (en) 2002-11-22 2004-06-18 Chugai Seiyaku Kabushiki Kaisha Antibody against lesion tissue
US7993864B2 (en) * 2002-12-03 2011-08-09 Ucb Pharma S.A. Assay for identifying antibody producing cells
JP2006517109A (ja) * 2003-02-07 2006-07-20 プロテイン デザイン ラブス インコーポレイテッド アンフィレグリン抗体ならびに癌および乾癬を処置するためのその使用
WO2004078776A2 (en) * 2003-03-04 2004-09-16 Ludwig Institute For Cancer Research Ny-eso-1 peptides which bind to class ii molecules and uses thereof
WO2005000870A2 (en) 2003-05-30 2005-01-06 Ludwig Institute Of Cancer Research Isolated ny-eso-1 peptides which bind to hla class ii molecules and uses thereof
GB0409940D0 (en) 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
US8399200B2 (en) 2004-05-26 2013-03-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Isolation of allergen-specific immunoglobulin genes from human B-cells from atopy sufferers
GB0412973D0 (en) * 2004-06-10 2004-07-14 Celltech R&D Ltd Identification of antibody producing cells
DE102006027224B3 (de) 2006-06-12 2008-01-03 Repower Systems Ag Windenergieanlage mit einer autarken Energieversorgung für eine Blattverstelleinrichtung
PT2099826E (pt) 2007-01-05 2014-01-09 Univ Zuerich Anticorpo anti-beta-amilóide e suas utilizações

Also Published As

Publication number Publication date
BRPI0808940A2 (pt) 2014-08-19
JP5797687B2 (ja) 2015-10-21
PT2457928T (pt) 2017-08-17
BRPI0808940B1 (pt) 2019-10-08
AU2008225994A1 (en) 2008-09-18
IL200615A (en) 2017-05-29
HUE035762T2 (en) 2018-05-28
WO2008110372A1 (en) 2008-09-18
EP2457928B1 (en) 2017-05-10
DK2457928T3 (en) 2017-08-28
CN101652388A (zh) 2010-02-17
AU2008225994B2 (en) 2014-12-11
EP2125888B1 (en) 2015-12-02
JP2010520760A (ja) 2010-06-17
ES2523194T3 (es) 2014-11-21
RU2009137784A (ru) 2011-04-20
EP2457928A2 (en) 2012-05-30
PL2457928T3 (pl) 2017-10-31
EP2457928A3 (en) 2012-06-20
ZA200905874B (en) 2010-04-28
US8519106B2 (en) 2013-08-27
BRPI0808940A8 (pt) 2019-02-05
CN101652388B (zh) 2013-12-25
RU2488593C2 (ru) 2013-07-27
CA2680914C (en) 2019-06-18
EP2134746B1 (en) 2014-08-06
KR20100014690A (ko) 2010-02-10
ES2637214T3 (es) 2017-10-11
US20100330075A1 (en) 2010-12-30
CA2680914A1 (en) 2008-09-18
AU2008225994B9 (en) 2014-12-18
BRPI0808940B8 (pt) 2021-05-25
EP2134746A1 (en) 2009-12-23
KR101570702B1 (ko) 2015-11-23
IL200615A0 (en) 2010-05-17
WO2008110373A1 (en) 2008-09-18
NZ579520A (en) 2012-06-29
JP2013223494A (ja) 2013-10-31
MX2009009926A (es) 2010-03-15
EP3159355A1 (en) 2017-04-26
EP2125888A1 (en) 2009-12-02
US20110123447A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
HRP20181616T1 (hr) Potpuno ljudska anti-vap-1 monoklonska antitijela
IL200615A0 (en) Monoclonal human tumor-specific antibody
IL200610A0 (en) Human monoclonal anti-ip-10 antibodies and uses thereof
IL197158A0 (en) Antagonistic human light-specific human monoclonal antibodies
SG10201604258YA (en) Anti-tnf antibody formulations
EP2021373A4 (en) MONOCLONAL ANTIBODY VCAM-1 SPECIFIC
ZA201002422B (en) Modified antibody constant region
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
IL191340A (en) Monoclonal antibodies against e8o
SG10201601279SA (en) Monoclonal Antibody STRO-4
IL202648A0 (en) Antibody formulations
IL202950A0 (en) Antibody formulations
SI2146745T1 (sl) Penta-specifično protitelo
IL204835A0 (en) Humanized antibody
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
EP2173163A4 (en) ANTIBODY FORMULATIONS
PL2188313T3 (pl) Białka wiążące ludzki antygen c-fms
IL205073A0 (en) Anti-bst2 antibody
ZA200901165B (en) Antagonistic human light-specific human monoclonal antibodies
ZA200901481B (en) Smallpox monoclonal antibody
EP2167635A4 (en) ANTIBODY FORMULATIONS
ZA200804254B (en) Human monoclonal antibodies to O8E
GB0706964D0 (en) Humanized antibody
GB0706963D0 (en) Humanized antibody
GB0706965D0 (en) Humanized antibody